Deferasirox as adjunctive therapy for mucormycosis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 519-520

  Donnelly, J Peter ^a   Lahav, Meir ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antifungal therapy; Iron and infection; Iron chelation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DEFERASIROX; PLACEBO; SIDEROPHORE;

ADJUVANT THERAPY; ANTIFUNGAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; IRON CHELATION; IRON METABOLISM; MORTALITY; MUCORMYCOSIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; YERSINIOSIS;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BENZOIC ACIDS; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MUCORMYCOSIS; TRIAZOLES;

EID: 84856977473     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr540     Document Type: Article

References (7)

1. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The Deferasirox- AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67: 715-22.
2. Reyes HM, Tingle EJ, Fenves AZ et al. Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy. Proc (Bayl Univ Med Cent) 2008; 21: 378-81.
3. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
4. Kontoghiorghes GJ, Spyrou A, Kolnagou A. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption. Hemoglobin 2010; 34: 251-64.
5. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-5.
6. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
7. Ibrahim AS, Edwards JE Jr, Bryant R et al. Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? Med Mycol 2009; 47: 592-600.